 The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Incs NYSE: CYBN psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The trial will be conducted at the University of Washington. 